This document discusses therapeutic drug monitoring (TDM) of drugs used to treat cardiovascular diseases. It focuses on digoxin, which is commonly used to treat congestive heart failure. The document provides details on digoxin's pharmacokinetic parameters, indications, therapeutic range, toxicity, and interactions with other medications. It emphasizes the importance of TDM for digoxin to ensure therapeutic levels are achieved and toxicity is avoided, especially when other medications are involved due to the risk of interactions.
Therapeutic drug monitoring (TDM) of drugs used in seizure disordersAbel C. Mathew
Therapeutic drug monitoring (TDM) of drugs used in seizure disorders- Phenytoin, Valproic acid, Carbamazepine are major drugs used in epilepsy disorders. These drug need TDM to ensure their proper usage.
Therapeutic drug monitoring (TDM) of drugs used in seizure disordersAbel C. Mathew
Therapeutic drug monitoring (TDM) of drugs used in seizure disorders- Phenytoin, Valproic acid, Carbamazepine are major drugs used in epilepsy disorders. These drug need TDM to ensure their proper usage.
adaptive methods are doing with feedback in population pharmacokinetics---- clinical pharmacokinetics and therapeutic drug monitoring-- fifth pharm D notes
Nomograms and tabulations in design of dosage regimens pavithra vinayak
Nomograms and tabulations in the design of dosage regimens --- NOMOGRAM IN UREMIC PATIENTS: NOMOGRAM FOR RELATIONSHIP BETWEEN CREATININE CLEARANCE AND ELIMINATION RATE CONSTANT FOR FOUR DRUGS clinical pharmacokinetics and therapeutic drug monitoring ---fifth PharmD notes
Bayesian theory in population pharmacokinetics--
1) INTRODUCTION TO BAYESIAN THEORY
2)BAYESIAN PROBABILITY TO DOSING OF DRUGS
3)APPLICATIONS AND USES OF BAYESIAN THEORY IN APPLIED PHARMACOKINETICS:
therapeutic drug monitoring and clinical pharmacokinetics-fifth pharm d notes
Genetic polymorphism in drug transport and drug targets.pavithra vinayak
Genetic polymorphism in drug transport and targets.--pharmacogenetics
DRUG TRANSPORTER
Two types of transporter :
•ATP binding Cassette (ABC) – Found in ABCB, ABCD and ABCG family. Associated with multidrug resistance (MDR) of tumor cells causing treatment failure in cancer.
•Solute Carrier (SLC) – Transport varieties of solute include both charged or uncharged
P-glycoprotein
• ATP binding cassette subfamily B member- 1 (ABCB 1)
• Multidrug resistance protein 1 (MDR1)
• Transport various molecules, including xenobiotic, across cell membrane
• Extensively distributed and expressed throughout the body
Mechanism of Pglycoprotein
Substrate bind to P-gp form the inner leaflet of the membrane
ATP binds at the inner side of the protein
ATP is hydrolyzed to produce ADP and energy
conversion from INTRAVENOUS TO ORAL DOSING----- design of dosage regimenpavithra vinayak
conversion from INTRAVENOUS TO ORAL DOSING----- TYPES OF IV TO PO THERAPY CONVERSIONS: MEDICATIONS INCLUDED IN AN IV TO PO CONVERSION PROGRAM: SELECTION OF PATIENTS FOR IV TO PO THERAPY CONVERSION: design of dosage regimen--clinical pharmacokinetics and therapeutic drug monitoring-- fifth pharm D notes
adaptive methods are doing with feedback in population pharmacokinetics---- clinical pharmacokinetics and therapeutic drug monitoring-- fifth pharm D notes
Nomograms and tabulations in design of dosage regimens pavithra vinayak
Nomograms and tabulations in the design of dosage regimens --- NOMOGRAM IN UREMIC PATIENTS: NOMOGRAM FOR RELATIONSHIP BETWEEN CREATININE CLEARANCE AND ELIMINATION RATE CONSTANT FOR FOUR DRUGS clinical pharmacokinetics and therapeutic drug monitoring ---fifth PharmD notes
Bayesian theory in population pharmacokinetics--
1) INTRODUCTION TO BAYESIAN THEORY
2)BAYESIAN PROBABILITY TO DOSING OF DRUGS
3)APPLICATIONS AND USES OF BAYESIAN THEORY IN APPLIED PHARMACOKINETICS:
therapeutic drug monitoring and clinical pharmacokinetics-fifth pharm d notes
Genetic polymorphism in drug transport and drug targets.pavithra vinayak
Genetic polymorphism in drug transport and targets.--pharmacogenetics
DRUG TRANSPORTER
Two types of transporter :
•ATP binding Cassette (ABC) – Found in ABCB, ABCD and ABCG family. Associated with multidrug resistance (MDR) of tumor cells causing treatment failure in cancer.
•Solute Carrier (SLC) – Transport varieties of solute include both charged or uncharged
P-glycoprotein
• ATP binding cassette subfamily B member- 1 (ABCB 1)
• Multidrug resistance protein 1 (MDR1)
• Transport various molecules, including xenobiotic, across cell membrane
• Extensively distributed and expressed throughout the body
Mechanism of Pglycoprotein
Substrate bind to P-gp form the inner leaflet of the membrane
ATP binds at the inner side of the protein
ATP is hydrolyzed to produce ADP and energy
conversion from INTRAVENOUS TO ORAL DOSING----- design of dosage regimenpavithra vinayak
conversion from INTRAVENOUS TO ORAL DOSING----- TYPES OF IV TO PO THERAPY CONVERSIONS: MEDICATIONS INCLUDED IN AN IV TO PO CONVERSION PROGRAM: SELECTION OF PATIENTS FOR IV TO PO THERAPY CONVERSION: design of dosage regimen--clinical pharmacokinetics and therapeutic drug monitoring-- fifth pharm D notes
pathology and Complications of type 2 diabetes mellitusAiswarya Thomas
explains in detail abou various complications of diabetes mellitus and its pathophysiology. Described about the peripheral, microvascular, macrovascular comlpication
Malaria, its pathology, epidemiology and clinical manifestationsAiswarya Thomas
discussed about what is malaria, what are the causetive organisms of malaria, what are the reasons for malaria, what are the symptoms of malaria, how can it be diagnosed, what are the risk factors, how can it be prevented etc. also dicusses about the life cycle of malaria
This presentation include a short description about the importance of family planning, various methods such as biological, mechanical, chemical and biological methods that are adopted in family planning and role of pharmacist in family planning etc.methods include mainly usage of pills, condoms, abstinance, withdrawal, IUDs, and terminational methods such as vasectomy and tubectomy
Syphilis and gonorrhea - Its etiology, pathophysiology, signs and symptoms,di...Aiswarya Thomas
Discussed about Syphilis and gonorrhea - Its etiology, pathophysiology, signs and symptoms,diagnosis and prevention. Also dicussed about the classifications of both STDs and its diagnostic tests
discusses about the effect of radiation that is hazardous to man and other living beings, how does these effects occur, and the necessity of minimizing the exposure to harmfull radiation
CLASS I: SODIUM CHANNEL BLOCKERS
Drugs block cardiac sodium channels. So, they decrease conduction velocity in the atria.
This drugs fall into five groups
CLASS I A ; agents delay repolarization
CLASS IB; agents accelerate repolarization
CLASS IC; agents have limited effect on repolarization
1. TDM OF DRUGS USED
IN CARDIOVASCULAR
DISEASES
SENTHIL RAJ V.
PHARM. D. Vth YEAR
2. CARDIOVASCULAR DISEASES
• Cardiovascular drugs are primarily used for the
treatment of angina, arrhythmias & congestive
heart failure.
• Digoxin, used in Congestive heart failure, is
widely prescribed and therapeutically monitored.
• Monitoring & use of anti-arrhythmics such as
disopyramide and lidocaine have been steadily
declining.
• Immunoassay are the used currently the most
popular methods of measuring cardiac drugs.
4. PHARMACOKINETIC PARAMETERS OF
FEW CARDIAC DRUGS
DRUG HALF
LIFE
TIME TO
STEADY
STATE
Vd L/Kg %
PROTEIN
BINDING
THERAPEUTIC
RANGE mg/L
TOXIC
CON.
mg/L
Digitoxin 100-200
days
1 month 0.54 ±
0.14
90 0.01-0.03 >2.5
Digoxin 26-52 5-7 days 7.30 23 0.0005-0.002 >0.003
DisopyramiD
e
5.0-7.0 1-2days 0.59 ±
0.15
28-68 2.0-5.0 >7.0
FlecainiDe 8.0-14 3-5days 4.9 ± 0.4 32-58 0.2-1.0 >1.0
liDocaine 1.4-2.2 0.5-1.5hr
(with
loading
dose);5-
10hr
(without
loading
dose)
1.1 ± 0.4 43-60 1.5-5.0 >6.0
5. CARDIAC GLYCOSIDES
• Digoxin is a cardiac glycoside indicated in the
treatment of atrial fibrillation (AF) and heart failure
(HF).
• Digoxin’s mechanism of action is thought to be
mediated through inotropic effects and
neurohormonal effects.
• Positive inotropic effects from digoxin arise from the
inhibition of Na+–K+-ATPase and secondary
activation of the Na+–Ca2+ membrane exchange
pump resulting in increased force of cardiac
contraction.
6. INDICATIONS FOR TDM DURING
DIGOXIN THERAPY INCLUDES
• Confirmation of toxicity (in the presence of
symptoms of digoxin toxicity)
• Assessing the effect of factors that alter
digoxin’s pharmacokinetics (e.g. renal
impairment, drug interactions)
• Initiating therapy or dose changes (in patients
with renal impairment)
• Therapeutic failure
• Medication adherence
7. SIGNS AND SYMPTOMS OF
TOXICITY
• Common
– Nausea, vomiting, anorexia, fatigue, confusion
• Rare or dose dependant
– Visual disturbances (blurred vision, green-yellow
colour disturbances)
– Cardiac arrhythmias
8. THERAPEUTIC RANGE
Heart failure
– 0.6nmol/L – 1.2nmol/L,
– Toxicity more likely >2.5nmol/L,
– Small increase in mortality with con. >1.5nmol/L.
Atrial Fibrillation (AF)
– 0.6 – 2nmol/L,
– Toxicity more likely >2.5nmol/L
– Serum digoxin levels correlate poorly with ventricular rate.
– In patients who are symptomatic, a low digoxin level may
indicate the patient could benefit from a dose increase.
9. MONITORING REQUIREMENTS
DIGOXIN THERAPY
• Digoxin therapy for HF symptoms has been shown to be
effective at lower concentrations (0.6 to 1.2 nmol/L).
• Therapy in lower concentrations was associated with a small
but significant reduction in all-cause mortality, worsening
heart failure, all-cause hospitalisation and hospitalisation due
to heart failure compared with placebo.
• Higher concentrations (>1.5nmol/L) were associated with a
small but significant increase in all-cause mortality,
cardiovascular mortality and hospitalisation for digoxin-related
toxicity.
to be continued…..
10. • The indications for digoxin TDM are relatively few and
include confirmation of clinically suspected toxicity,
assessing the reasons for therapeutic failure, assessing
medication adherence, and assessing the effects of
factors that alter the pharmacokinetics of digoxin
(predominantly renal dysfunction and drug interactions).
• Samples for digoxin TDM should be taken at least six to
eight hours after the last dose, or ideally immediately
before the next dose.
to be continued…..
11. • This allows for the redistribution of digoxin from plasma
into the tissues.
• It is ideal that digoxin levels are taken when
concentrations are at steady-state.
• The relatively long half-life of digoxin (30 hours in
patients with normal renal function) means that following
initiation or dose alterations, it takes at least 7 days for
steady-state concentrations to be achieved.
• In the elderly with impaired renal function the half life can
be extended to 3.5-5days, meaning 14-20days may be
required before steady state is acheived.
12. ACTIONS ON THERAPEUTIC
LEVEL
• Serum digoxin levels should be interpreted within the
clinical context.
• If the level is above the therapeutic range, the dose
should be reduced even if toxicity is not observed.
• This is based on the observation that the patient is at risk
of arrhythmia, and no further clinical benefit is likely with
higher concentrations.
• Toxicity is observed when digoxin levels are within the
normal range, due to other factors which alter tissue
sensitivity to digoxin.
to be continued…..
14. • Digoxin TDM may be useful to detect the
patients who have a low digoxin concentration
and who may benefit from an increase in digoxin
dose, as opposed to those with higher
concentrations who are likely to develop toxicity
symptoms only from an increase in dose.
15. MEDICATION INTERACTIONS
• Digoxin is rapidly absorbed with a bioavailability of 70-
80% from oral tablets.
• Digoxin is eliminated primarily by renal excretion, via P-
glycoprotein (P-gp).
• Interactions with digoxin are mediated through the
inhibition or induction of P-gp in the GI tract and renally.
• Inhibition of renally located P-gp results in increased
serum digoxin levels.
• Induction of P-gp in the gut reduces digoxin absorption,
resulting in lower levels.
16. MEDICATIONS WHICH INCREASE
THE RISK OF TOXICITY
• Reduce the dose of digoxin prior to initiating therapy:
– Amiodarone (50% dose reduction when initiating amiodarone)
– Verapamil (50% dose reduction when initiating verapamil)
• Monitor digoxin level (7 days-21 days depending on
renal function after introducing the interacting medicine)
– Clarithyromycin / erythromycin / roxithromycin
– Spironolactone
– Cyclosporin
– Itraconazole
– Diltiazem
– Quinine
– Atorvastatin (high doses only 80mg daily)
– Trimethoprim (courses >7 days)
17. • Monitor renal function and potassium level
(every 3-6 months or after vomiting,
diarrhoea or dehydration)
– Diuretics (risk of hypokalaemia)
– ACE-Inhibitors (reduction in renal function –
monitor 7 days after starting then 3-6 monthly)
18. MEDICATIONS WHICH DECREASE
DIGOXIN LEVELS
• Decreased absorption (Monitor Levels 7-21 days after
introducing the interacting medicine)
– Rifampicin
– St John’s Wort
• Decreased absorption (separate administration by 2
hours)
– Antacids (aluminium and magnesium, not calcium based)
19. REFERENCES
• Standards Of Laboratory Practice: Cardiac Drug
Monitoring By Roland Valdes Jr.
• Aged Residential Care Digoxin Monitoring Guidelines
Version 2 2013.
• Appropriateness Of Digoxin Level Monitoring By Mara R.
Mordasinia.
• Cardiovascular Drug Therapy In The Elderly Wilbert S.
Aronow.